On Jun 30, 2021 NeuroPace was awarded by $9,300,000 Grant from National Institutes of Health. The Grant will provide up to $9.3 million over five years to evaluate the use of NeuroPace’s RNS® System to treat Lennox-Gastaut Syndrome (LGS).

About the company: Neurospace is an american medical technology company dedicated to transforming the lives of people suffering from epilepsy “The NeuroPace RNS System is the only FDA-approved epilepsy device that delivers personalized treatment by responding to abnormal brain activity and provides EEG data that can help improve patient care.”

Company website: www.neuropace.com